prostaglandin-e3 has been researched along with Neoplasms* in 2 studies
1 review(s) available for prostaglandin-e3 and Neoplasms
Article | Year |
---|---|
Prostaglandin E3 metabolism and cancer.
The anticancer activity of n-3 fatty acids, especially those derived from fish, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid) (DHA), has been studied for centuries. While there is a growing body of evidence that EPA and DHA may influence cancer initiation and development through targeting multiple events of tumor development, the underlying mechanisms responsible for these activities are still not fully understood. A number of studies have suggested that the anticancer activities of EPA and DHA are associated with their effects on eicosanoid metabolism by which they inhibit prostaglandin E2 (PGE2) production. In contrast to DHA, EPA can function as a substrate for cyclooxygenases (COXs) to synthesize unique 3-series prostaglandin compounds, especially PGE3. With advance technology in mass spectrometry, there is renewed interest in studying the role of PGE3 in EPA elicited anti-proliferative activity in various cancers, with some promising results. Here, we summarize the regulation of PGE3 synthesis in cancer cells and its role in EPA elicited anticancer activity. The development of PGE3 and its metabolites as potential biomarkers for future clinical evaluation of EPA and fish oil in cancer care is discussed. Topics: Alprostadil; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cyclooxygenase 2; Dinoprostone; Eicosapentaenoic Acid; Group IV Phospholipases A2; Humans; Neoplasms; Signal Transduction | 2014 |
1 other study(ies) available for prostaglandin-e3 and Neoplasms
Article | Year |
---|---|
Modulation of angiogenesis by omega-3 polyunsaturated fatty acids is mediated by cyclooxygenases.
The potential role of dietary fats in cancer is attracting considerable interest within the community. Both epidemiologic and experimental findings suggest that omega-3 polyunsaturated fatty acids (omega-3 PUFAs), which are almost absent from typical Western diets, exert protective effects against cancer progression, although the precise mechanism of this suppression remains unknown. One of the potential targets for omega-3 PUFAs in cancer suppression is angiogenesis, a process of new blood vessel formation within rapidly growing tumors. Here, we demonstrate that omega-6 PUFAs stimulate and omega-3 PUFAs inhibit major proangiogenic processes in human endothelial cells, including the induction of angiopoietin-2 (Ang2) and matrix metalloprotease-9, endothelial invasion, and tube formation, that are usually activated by the major omega-6 PUFA arachidonic acid. The cyclooxygenase (COX)-mediated conversion of PUFAs to prostanoid derivatives participated in modulation of the expression of Ang2. Thus, the omega-6 PUFA-derived prostaglandin E2 augmented, whereas the omega-3 PUFA-derived prostaglandin E3 suppressed the induction of Ang2 by growth factors. Our findings are consistent with the suggestion that PUFAs undergo biotransformation by COX-2 to lipid mediators that modulate tumor angiogenesis, which provides new insight into the beneficial effects of omega-3 PUFAs. Topics: Alprostadil; Angiopoietin-2; Arachidonic Acid; Cells, Cultured; Cyclooxygenase 2; Dinoprostone; Endothelial Cells; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Humans; Matrix Metalloproteinase 9; Neoplasms; Neovascularization, Pathologic | 2008 |